Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed mantle cell lymphoma~  * Relapsed disease~* Not refractory to prior therapy~  * Must have received 1-3 prior systemic chemotherapy regimens AND has had no disease progression while receiving chemotherapy or within 1 month of last dose of most recent therapy~* Clinically and/or radiologically documented disease~  * At least 1 site of disease must be bidimensionally measurable by CT scan or MRI with ≥ 1 lesion meeting 1 of the following criteria:~    * Lymph nodes ≥ 1.5 cm x 1.5 cm by spiral CT scan~   * Non-nodal lesion ≥ 1 cm x 1 cm by MRI, CT scan, or physical exam~ * No nonmeasurable disease only~* No preexisting ascites or pleural effusion ≥ grade 2~* No known CNS involvement by lymphoma~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy ≥ 12 weeks~* Absolute granulocyte count ≥ 1,500/mm³~* Platelet count ≥ 75,000/mm³~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN~* AST or ALT ≤ 2.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* LVEF ≥ 45% by echocardiogram or MUGA~* No history of allergic reactions attributed to compounds containing boron or mannitol~* No preexisting edema ≥ grade 2~* No preexisting neuropathy (sensory and/or pain) ≥ grade 2~* No preexisting shortness of breath ≥ grade 2~* No history of other malignancies, except adequately treated nonmelanoma skin cancer, curatively treated in situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥ 5 years~* No other serious illness or medical condition that would preclude compliance with study requirements, including any of the following:~  * Serious uncontrolled infection~ * Uncontrolled or severe cardiovascular disease, including any of the following:~    * Myocardial infarction within the past 6 months~   * New York Heart Association class III-IV heart failure~   * Uncontrolled angina~   * Clinically significant pericardial disease~   * Cardiac amyloidosis~ * Significant neurological disorder~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 6 weeks since prior chemotherapy~* No prior radioactive monoclonal antibody therapy~* No prior bortezomib~* No prior investigational therapy (except for flavopiridol)~* No prior radiotherapy to \> 25% of functioning bone marrow~* At least 4 weeks since prior radiotherapy and recovered~  * Low-dose, nonmyelosuppressive radiotherapy may be allowed~* At least 2 weeks since prior major surgery~* No other concurrent anticancer therapy~* No concurrent corticosteroids~* No other concurrent cytotoxic chemotherapy~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Bortezomib + Gemcitabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).